PHILADELPHIA - A team of researchers co-led by the University of Pennsylvania has developed and tested a new high-resolution, ultra-thin device capable of recording brain activity from the cortical surface without having to use penetrating electrodes. The device could make possible a whole new generation of brain-computer interfaces for treating neurological and psychiatric illness and research. The work was published in Nature Neuroscience.
"The new technology we have created can conform to the brain's unique geometry, and records and maps activity at resolutions that have not been possible before," says Brian Litt, MD, the study’s senior author and Associate Professor of Neurology at the Perelman School of Medicine and Bioengineering at the University of Pennsylvania. "Using this device, we can explore the brain networks underlying normal function and disease with much more precision, and its likely to change our understanding of memory, vision, hearing and many other normal functions and diseases." For our patients, implantable brain devices could be inserted in less invasive operations and, by mapping circuits involved in epilepsy, paralysis, depression and other 'network brain disorders' in sufficient detail, this could allow us to intervene to make patients better, Litt said.
Composed of 720 silicon nanomembrane transistors in a multiplexed 360-channel array, the newly designed ultrathin, flexible, foldable device can be positioned not only on the brain surface but also inside sulci and fissures or even between the cortical hemispheres, areas that are physically inaccessible to conventional rigid electrode arrays. Current arrays also require separate wires for each individual sensor, meaning that they can sample broad regions of the brain with low resolution or small regions with high resolution, but not both. The multiplexed nanosensors of the new device can cover a much large brain area with high resolution, while using almost ten times fewer wires.
Monitoring and studying the brain’s constant electrical activity, or to alter it when it goes awry, often requires the placement of electrodes deep within specific regions of the brain. These currently used devices can be clumsy and of low resolution, and those used for neuromotor prostheses can cause tissue inflammation and hemorrhages.
Study collaborators including lead author Jonathan Viventi, PhD, an assistant professor at the Polytechnic Institute of New York University who worked with Litt on the project as a postdoctoral fellow at Penn, and colleagues John Rogers from the University of Illinois Urbana-Champaign, and Dae-Hyeong Kim from Seoul National University, worked together to conceive and build the array, believed to be the first device of its kind to be used as a brain interface.
In animal models, researchers observed responses to visual stimuli and recorded previously unknown details of sleep patterns and brain activity during epileptic seizures. The array recorded spiral waves during seizure activity that have not been previously recorded in whole brain. These patterns are similar to those seen in the heart during ventricular fibrillation, raising the possibility of fighting epilepsy with some of the same methods used to treat cardiac arrhythmias, like focal destruction or ablation of abnormal circuits.
The observation of spiral wave activity also served to highlight the extreme sensitivity and resolving capacity of this new active array, which was able to easily distinguish normal signal patterns from abnormal waves even in the same frequency ranges. The activity recorded by Litt’s research team has enormous implications not only for controlling seizures but for understanding and treating disorders of other brain processes affecting sleep, memory, and learning, and for the characterizing and treating chronic pain, depression, and other neuropsychological disorders.
Ultimately, the researchers expect that flexible electrode arrays can be perfected for use for various therapeutic and research purposes throughout the body. They could serve as neuroprostheses, pacemakers, ablative devices, or neuromuscular stimulators. Their versatility, sensitivity, and reduced effect on surrounding tissues puts them in the forefront of the next generation of brain-computer interfaces.
In addition to the National Institutes of Health’s National Institute of Neurological Disorders and Stroke (NINDS), the research was supported by the National Science Foundation, the Division of Materials Sciences at the U.S. Department of Energy, Citizens United for Research in Epilepsy, the Dr. Michel and Mrs. Anna Mirowski Discovery Fund for Epilepsy Research, and NIH's National Heart, Lung, and Blood Institute.
###
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.